E. Robert Conway's most recent trade in Alpine Immune Sciences Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on May 20, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 50,000 | 0 (0%) | 0% | - | Common Stock | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 17,500 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 3,075 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 2,868 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 1,912 | 0 | - | - | Stock Option (Right to buy) | |
| Oruka Therapeutics Inc | Robert Conway E. | Director, Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Alpine Immune Sciences Inc | E. Robert Conway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| Oruka Therapeutics Inc | Robert E. Conway | Director, Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Purchase of securities on an exchange or from another person at price $ 10.08 per share. | 23 Sep 2021 | 15,000 | 50,000 (0%) | 0% | 10.1 | 151,154 | Common Stock |
| Alpine Immune Sciences Inc | Robert E. Conway | Director | Purchase of securities on an exchange or from another person at price $ 9.80 per share. | 21 Sep 2021 | 10,000 | 35,000 (0%) | 0% | 9.8 | 97,966 | Common Stock |
| Oruka Therapeutics Inc | Robert E. Conway | Director, Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 13 May 2021 | 10,000 | 50,000 (3%) | 0% | 3.2 | 31,947 | Common Stock |
| Oruka Therapeutics Inc | Robert E. Conway | Director, Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 3.23 per share. | 05 May 2021 | 10,000 | 40,000 (2%) | 0% | 3.2 | 32,345 | Common Stock |
| Oruka Therapeutics Inc | Robert E. Conway | Director, Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2021 | 12,000 | 12,000 | - | - | Stock Option (right to buy) |